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Background: Adenine phosphoribosyltransferase deficiency (APRTD) is an under estimated genetic form of kidney
stones and/or kidney failure, characterized by intratubular precipitation of 2,8-dihydroxyadenine crystals (2,8-DHA).
Currently, five pathologic allelic variants have been identified as responsible of the complete inactivation of
APRT protein.
Case presentation: In this study, we report a novel nonsense mutation of the APRT gene from a 47- year old Italian
patient. The mutation, localized in the exon 5, leads to the replacement of a cytosine with a thymine (g.2098C > T),
introducing a stop codon at amino acid position 147 (p.Gln147X).
This early termination was deleterious for the enzyme structural and functional integrity, as demonstrated by the
structure analysis and the activity assay of the mutant APRT protein.
Conclusion: These data revealed that the p.Gln147X mutation in APRT gene might be a new cause of APRT disease.
Keywords: APRT deficiency, Renal failure, Crystalline nephropathyBackground
Adenine phosphoribosyltransferase deficiency (APRTD)
is a rare autosomal recessive metabolic disorder due to
a mutation of the APRT gene [1]. APRT is a purine-
metabolism enzyme that catalyzes the formation of 5′-
adenosine monophosphate (5′-AMP) and pyrophosphate
(PP) from adenine and 5-phosphoribosyl-1-pyrophosphate
[2,3]. In patients with complete APRT deficiency, aden-
ine is oxidized by xanthine oxidase (XO) to the highly
insoluble and nephrotoxic derivative 2,8-dihydroxyadenine
(2,8-DHA) [4], leading to urolithiasis and renal failure
caused by intratubular crystalline precipitation [5,6].
The APRT gene, located on chromosome 16q24 [7], is
approximately 2.6 kb long, contains five exons and four
introns, and encodes a protein of 180 amino acid residues
[8]. The human enzyme, present in a variety of cell types
including erythrocyte [9], is a homodimer composed of* Correspondence: rea.valaperta@grupposandonato.it
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unless otherwise stated.two identical subunit species with a molecular weight of
about 19.481 Da [10]. Currently, there are two isoforms
produced by alternative splicing: the isoform 1 (P07741-1)
and the isoform 2 (P07741-2); the isoform 1 has been con-
sidered as the ‘canonical’ one.
In the pathologic allelic variants, more than 40 muta-
tions have been identified in the coding region of APRT
gene in over 300 affected individuals from more than 25
countries, including at least 200 individuals from Japan.
Approximately 10% of mutant alleles in affected white
individuals and 5% in affected Japanese haven’t been yet
identified. APRT gene alterations include missense, frame-
shift, and nonsense mutations and small deletions/inser-
tions ranging in size from 1 to 8 base pairs. The estimated
heterozygosity in different populations ranges from 0.4 to
1.2% [11], suggesting that the prevalence of a homozygous
state is at least 1:50,000 to 1:100,000.
Mutant alleles responsible for the disease have been
classified as APRT*Q0 for type I and APRT*J for type II
APRTD. Type I APRT deficiency (complete deficiencyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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different countries [12-15]. Type II deficiency (complete
enzyme deficiency in vivo but partial deficiency in cell
extracts) has been found mainly in Japan [16-18].
However, this distinction is only of historical interest,
because APRT enzyme activity in intact cells has been
shown to be approximately 1% in both types [19].
The most common mutations in affected European
individuals are: (i) T insertion at the intron 4 splice
donor site (IVS4 + 2insT) which leads to the deletion of
exon 4 from the mRNA because of aberrant splicing.
This mutation has been found in individuals from many
European countries as well as in an affected individual
from the US, (ii) A-to-T transversion in exon 3 (g.194A >T,
p.Asp65Val), described in affected individuals from Iceland,
Britain, and Spain. The three most common mutations
in affected Japanese individuals, in order of decreasing
frequency, are: (i) T-to-C missense mutation in exon 5
(g.442 T > C), (ii) G-to-A nonsense mutation in exon 3
(g.329G > A) and (iii) a four-base pair (CCGA) duplica-
tion in exon 3 that leads to a frameshift after codon
186 [20,21].
In the present study, we report the identification of
a new nonsense mutation (g.2098C > T) in exon 5
(p.Gln147X) of the APRT gene from an Italian patient
affected by APRT deficiency.Case presentation
Clinical history of the patient
The patient, born in 1964, was diagnosed as affected by
obstructive chronic kidney disease (CKD) with crystal-
luria at the age of 28. The serum creatinine was 4 mg/dl.
The composition of the crystals was not investigated.
Treatment with allopurinol and bicarbonate resulted in
modest and transient improvement of renal function.
In 2005, the patient started hemodialysis due to end stage
renal failure. In April 2010, at the age of 46, he received a
kidney transplant from a deceased donor. However, the
disease rapidly recurred in the transplanted organ on
the 9th day after the transplant and the concentrations
of creatinine and urea were 7.7 mg/dl and 204 mg/dl,
respectively. Two weeks after kidney transplant, a renal
biopsy was performed and showed chronic tubulointersti-
tial nephropathy. Urinary sediment showed precipitations
typical of 2,8-DHA crystals. After the diagnosis of APRT
deficiency the allopurinol dose was increased to 300 mg
twice a day. The patient was dismissed on May 2010
with a 2 mg/dl concentration of creatinine. In October
2010, he was again hospitalized for a bacterial lung
infection. The patient’s general conditions worsened
because of the onset of a multiorgan dysfunction and
septic shock. The patient died in 2011, 10 months after
the transplantation.Diagnosis of APRT deficiency
The diagnosis of APRT deficiency disease in our patient
was confirmed by: (i) the absence of APRT enzyme
activity in erythrocytes, (ii) the characterization of 2,8-
DHA crystals in the urinary sediment and in the renal
biopsy, (iii) the measurement of levels of adenine in a
24-hour urine specimen, (iv) the molecular analysis of
the APRT gene.
High performance liquid chromatography (HPLC) ana-
lysis was used to measure APRT enzymatic activity in
erythrocyte lysates and the levels of adenine were mea-
sured in 24-hour urine with UV detection [22].
The APRT activity was determined by calculating the
AMP produced by hemolysates during the incubation
with substrates over the basal hemolysate value, measured
in a PRPP starved reaction.
The APRT activity in the patient was about 1%: residual
APRT activity was 0.8 μmol/min/mg of hemoglobin while
in control individuals the mean value was 36.1 ± 3.2 μmol/
min/mg. The concentration of adenine in the patient’s
urine was 15.68 mmol per mol of creatinine while in the
control range it is 0.18-0.20 mmol per mol of creatinine.
Light microscopy analysis a kidney section from a biopsy
taken two weeks after transplantation, presented irregular
aggregates in most of the tubules in the renal cortex. The
analysis by polarized microscopy showed precipitation of
2,8-DHA crystals within tubular lumen and interstitium
(Figure 1A). At the same time, all urine samples were
positive for small and medium sized 2,8-DHA crystals.
Microscopic examination revealed multiple spherical and
reddish-brown particles with a dark outline and central
spicules, that look like “Maltese crosses” under polarized
light. The 2,8-DHA crystals had atypical appearances with
unusual birefringence features (Figure 1B and C).
Molecular analysis
Direct DNA sequencing, by Sanger method, of the five
exons and their flanking regions showed that our patient
was homozygous for a polymorphism in flanking region
2 named rs8191483. He was also carrying a homozygous
nonsense mutation in exon 5 in position g.2098C > T
that introduced a stop codon at amino acid position 147
(p.Gln147X). The sequence analysis of the APRT gene
from a healthy donor was used as control (Figure 2A).
The homozygous nature of this site was confirmed by
the presence of only one peak in the chromatogram on
both strands of genomic DNA (Figure 2B). The C > T
replacement at this site leads to the formation of a
truncated protein of 147 amino acids, compared to the
normal 180 amino acid protein (Figure 2C). The Gln147X
mutation has not been reported in previous studies, sug-
gesting that this is a new nonsense mutation. Fifty healthy
donor were used as controls. The p.Gln147X mutation
was not found in any of them. The nomenclature used to
Figure 1 Characterization of 2,8-DHA crystals. (A) renal biopsy. Haematoxylin and myosin staining of a frozen section reveals interstitial
inflammation surrounding multiple intra-tubular round brownish crystal that are birefringent under polarized light. (B, C) Urinary miscroscopy.
Urinary sediment showing spherical brownish crystal that have a birefringent aqnd pseudo-Maltese cross appearance under polarized light.
Magnifications: ×100 in A, ×40 in B and C.
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Den Dunnen and Antonarakis [23] and by the Human
Genome Variation Society (HGVS).
Unfortunately, the pedigree has not been investigated
in our study since the family members refused genetic
investigation.
Protein analysis
Erythrocytes isolation from peripheral blood of a control
individual and from our patient was performed by Ficoll/
Paque density separation protocol. Purity was confirmed
by flow cytometry with a mouse anti-human-CD45 PE
(Figure 3A) and anti-CD235a PerCP-eFluor710 (Figure 3B)
monoclonal antibodies. SDS-PAGE protein analysis re-
vealed the lack of the C-terminal domain in the patient
sample compared to control. The N-terminal domain,
used as internal control, was present in both samples
(Figure 3C). Western blot analysis was performed using
rabbit polyclonal APRT antibody (C-term) (Abgent, Cat
AP2893b) and rabbit polyclonal APRT antibody (N-term)
(Abgent, Cat AP2893a).
To analyze the structural impact of the p.Gln147X
nonsense mutation on APRT, the 3-D structure of the
protein was modeled based on the solved protein struc-
ture (PDB ID: 1ORE) using Swiss-PdbViewer software.
We reported the loss of the C-terminal of the APRT
protein which includes a portion of the S8 strand, the S9
strand and the H6 α-helix, due to the new identified
nonsense mutation (Figure 4A). The lack of this portion
of the protein led to the removal of Leu159 residue,
present in the protein active site (Figure 4B).
To evaluate the hydropathicity of both the wild type
and the mutated protein, the Grand Average of Hydro-
pathicity (GRAVY) was calculated with ProtParam Tool
[24]. Loss of the C-terminal domain also caused an alter-
ation in the protein hydrophobicity: the GRAVY of the
wild type protein is 0.104, whereas the GRAVY of the
mutated protein is 0.058, indicating that the mutated
form of the protein is more hydrophilic than the wild
type one.Conclusion
APRT deficiency is a disease caused by mutations in the
APRT gene. There are more than 40 types of mutations
in APRT gene, but currently only five allelic variants are
responsible for the complete inactivation of the APRT
protein both in vitro and in vivo.
This disease is characterized by the presence of 2,8-
DHA crystals in urine. These crystals are radiolucent
and are often considered as uric acid stones or, in renal
biopsies, as oxalate crystals, causing an erroneous diagno-
sis. Ultraviolet or infrared spectrophotometry is required
for their correct identification.
Accurate diagnosis of APRT deficiency is crucial because
early treatment with allopurinol or low-purine diet effect-
ively prevents the stone formation and may improve
patients’ renal function. Nowadays, several diagnostic
tools are available for the identification of the APRT
deficiency such as 2,8-DHA crystal microscopic detection,
APRT enzyme activity assays and molecular analysis of
the APRT gene. In the present study, we analyzed an
Italian patient with a clinical history of recurrent nephro-
lithiasis and chronic renal failure due to obstructive
nephropathy and recurrent urinary tract infections.
The patient received a renal transplant in 2010 but,
unfortunately, he died 10 months after the surgical
procedure. The definitive diagnosis of APRT deficiency
was made by microscopic detection of 2,8-DHA crystals
on the biopsy of the failing transplanted kidney and by
documenting decreased APRT activity in red blood cells.
Genetic analysis revealed a combination of a previously
described homozygous state for rs8191483 SNP and a
novel nonsense mutation p.Gln147X. The identification of
two allelic variants in homozygous state suggest the con-
sanguinity in this family. The carriers are asymptomatic
and they are usually identified during family screening.
The normal human APRT is a protein of 180 amino
acids, composed of 9 β-strands and 6 α-helices, which
can be divided into the “core” (residues 33–169), the
“hood” (residues 5–34), and the “flexible loop” (residues
95–113) domains. On the basis of the APRT structure,
Figure 2 Chromatograms of a nonsense mutation in APRT gene located on chromosome 16q24. Sequence analysis of a wild type control
(A) and of patient’s DNA (B), on both strands of genomic DNA (C). The sequences from the wild type control are compared with the region including
the new nonsense mutation. Amino acid residues are numbered from the start codon of the open reading frame along with the nucleotide numbers.
The C > T replacement is indicated in red. The position of premature termination at amino acid 147 (p.Gln147X) in the mutant patient is indicated by
stop codon in the box.
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Ala131 and Leu159 are essential residues for the specific
recognition of adenine among different purines through
hydrophobic interactions. Moreover, the importance of
the Leu159 residue is also confirmed by the presence in
the same position of a lysine residue in the PRTases that
binds hypoxanthine, xanthine, or guanine. This difference
between residues located at the amino acid 159 positionexplains the specificity of type I PRTases for their respect-
ive purines [25].
The novel nonsense mutation reported in this study
caused the introduction of a stop codon leading to the
loss of 33 amino acids, corresponding to the C-terminal
domain of the APRT protein. This portion represents
the “core” of the APRT protein. In particular, the funda-
mental Leu159 residue, responsible for the correct activity
Figure 3 Characterization of APRT protein in erythrocyte lysate. Erythrocyte isolation from peripheral blood of a control and of patient by
Ficoll/Paque density separation protocol. Purity was confirmed in flow cytometry, staining target cells with mouse anti-human anti-CD45 PE
(leukocyte marker) (A) and anti-CD235a PerCP-eFluor710 (erythrocyte marker) monoclonal antibodies (B). (C) Western blot analysis performed by
C-terminal and N-terminal APRT antibodies in a wild type control and in our patient.
Figure 4 Model of 3D structure of APRT protein. (A) Ribbon diagram of the wild type (left) and truncated (right) APRT monomer. Truncated
protein lack the C-terminal domain which includes S8 and S9 b-strands and H6 a-helix. (B) Calyx-like structural feature of the active site of wild
type (left) and truncated (right) APRT monomer. The truncated form lack Leu159, an essential residue for the active site.
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fore, the complete inactivation of the APRT protein
reported in our patient is due to the impaired binding
of the specific substrate to the active site, since the
g.2098C > T mutation deeply affects the enzyme structural
integrity.
In conclusion, the novel nonsense mutation p.Gln147X
might be the main cause for the therapeutic failure ob-
served in our patient.
Moreover, the evidence of this novel “loss-of-function”
mutation might be extremely useful as a new genetic
diagnostic marker for the early identification of the
APRT deficiency.
More than 30 years have passed since the recognition of
the first mutation in the APRT gene but, although much
has been done during this period, the identification and
characterization of new mutations might be an important
step forward in the clinical practice for improving the
detection of this still underdiagnosed disease.
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